当前位置: X-MOL 学术Metabolism › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Metabolism ( IF 10.8 ) Pub Date : 2019-10-28 , DOI: 10.1016/j.metabol.2019.154001
Golnaz Ranjbar 1 , Dimitri P Mikhailidis 2 , Amirhossein Sahebkar 3
Affiliation  

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western societies and a major cause of hepatic disease worldwide. Its more severe type, namely nonalcoholic steatohepatitis (NASH), may result in the development of cirrhosis and hepatocellular carcinoma. NAFLD, and especially NASH, are also associated with increased cardiovascular morbidity and mortality. Type 2 diabetes mellitus (T2DM) predisposes to NAFLD development and progression via insulin resistance and hyperglycemia. It has also been reported that the majority of T2DM patients have NAFLD/NASH, thus potentially further increasing their cardiometabolic risk. Current guidelines recommend to screen for NAFLD in all T2DM patients and vice-versa. Lifestyle remains the first-line therapeutic option for NAFLD/NASH. Among antidiabetic drugs, pioglitazone was shown to improve histological features of NASH. More recently, there is an increasing interest regarding the effects of newer anti-diabetic drugs, such as dipeptidyl peptidase 4 inhibitors (DPP-4i), sodium glucose cotransporter 2 inhibitors (SGLT2i), and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on NAFLD/NASH. The present narrative review considers the up-to-date data on the impact of DPP-4i, SGLT2i, and GLP-1 RAs on biochemical and/or histological markers of NAFLD/NASH. The potential clinical implications of these findings in daily practice are also discussed. Taking into consideration the global increasing prevalence of NAFLD/NASH, therapeutic options that can prevent or treat this disease will exert considerable benefits on human health.

中文翻译:

新型抗糖尿病药对非酒精性脂肪肝和脂肪性肝炎的影响:开箱即用!

非酒精性脂肪性肝病(NAFLD)是西方社会最常见的慢性肝病,也是全世界肝病的主要原因。其更严重的类型,即非酒精性脂肪性肝炎(NASH),可能导致肝硬化和肝细胞癌的发展。NAFLD,尤其是NASH,也与心血管疾病的发病率和死亡率增加有关。2型糖尿病(T2DM)易通过胰岛素抵抗和高血糖而发展为NAFLD。还已经报道大多数T2DM患者患有NAFLD / NASH,因此潜在地进一步增加了他们的心脏代谢风险。当前的指南建议在所有T2DM患者中筛查NAFLD,反之亦然。生活方式仍然是NAFLD / NASH的一线治疗选择。在抗糖尿病药中,吡格列酮可改善NASH的组织学特征。最近,人们对新型抗糖尿病药物(例如二肽基肽酶4抑制剂(DPP-4i),钠葡萄糖共转运蛋白2抑制剂(SGLT2i)和胰高血糖素样肽1受体激动剂(GLP)的作用越来越感兴趣。 -1 RAs)。本叙述性评论考虑了有关DPP-4i,SGLT2i和GLP-1 RA对NAFLD / NASH的生化和/或组织学标志物影响的最新数据。还讨论了这些发现在日常实践中的潜在临床意义。考虑到全球范围内NAFLD / NASH的患病率上升,可以预防或治疗该疾病的治疗选择将对人类健康产生可观的益处。人们对新型抗糖尿病药物(例如二肽基肽酶4抑制剂(DPP-4i),钠葡萄糖共转运蛋白2抑制剂(SGLT2i)和胰高血糖素样肽1受体激动剂(GLP-1 RA) )在NAFLD / NASH上。本叙述性评论考虑了有关DPP-4i,SGLT2i和GLP-1 RA对NAFLD / NASH的生化和/或组织学标志物影响的最新数据。还讨论了这些发现在日常实践中的潜在临床意义。考虑到全球范围内NAFLD / NASH的患病率上升,可以预防或治疗该疾病的治疗选择将对人类健康产生可观的益处。人们对新型抗糖尿病药物(例如二肽基肽酶4抑制剂(DPP-4i),钠葡萄糖共转运蛋白2抑制剂(SGLT2i)和胰高血糖素样肽1受体激动剂(GLP-1 RA) )在NAFLD / NASH上。本叙述性评论考虑了有关DPP-4i,SGLT2i和GLP-1 RA对NAFLD / NASH的生化和/或组织学标志物影响的最新数据。还讨论了这些发现在日常实践中的潜在临床意义。考虑到全球范围内NAFLD / NASH的患病率上升,可以预防或治疗该疾病的治疗选择将对人类健康产生可观的益处。钠葡萄糖共转运蛋白2抑制剂(SGLT2i)和胰高血糖素样肽1受体激动剂(GLP-1 RA)对NAFLD / NASH的作用。本叙述性评论考虑了有关DPP-4i,SGLT2i和GLP-1 RA对NAFLD / NASH的生化和/或组织学标志物影响的最新数据。还讨论了这些发现在日常实践中的潜在临床意义。考虑到全球范围内NAFLD / NASH的患病率上升,可以预防或治疗该疾病的治疗选择将对人类健康产生可观的益处。钠葡萄糖共转运蛋白2抑制剂(SGLT2i)和胰高血糖素样肽1受体激动剂(GLP-1 RA)对NAFLD / NASH的作用。本叙述性评论考虑了有关DPP-4i,SGLT2i和GLP-1 RA对NAFLD / NASH的生化和/或组织学标志物影响的最新数据。还讨论了这些发现在日常实践中的潜在临床意义。考虑到全球范围内NAFLD / NASH的患病率上升,可以预防或治疗该疾病的治疗选择将对人类健康产生可观的益处。还讨论了这些发现在日常实践中的潜在临床意义。考虑到全球范围内NAFLD / NASH的患病率上升,可以预防或治疗该疾病的治疗选择将对人类健康产生可观的益处。还讨论了这些发现在日常实践中的潜在临床意义。考虑到全球范围内NAFLD / NASH的患病率上升,可以预防或治疗该疾病的治疗选择将对人类健康产生可观的益处。
更新日期:2019-10-28
down
wechat
bug